Coya Therapeutics, Inc.
COYA
$4.93
-$0.31-5.92%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.00K | -- | 3.43M | 126.80K | 6.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.00K | -- | 3.43M | 126.80K | 6.00M |
| Cost of Revenue | 1.94M | 2.22M | 4.57M | 3.14M | 1.61M |
| Gross Profit | -1.94M | -2.22M | -1.14M | -3.01M | 4.39M |
| SG&A Expenses | 2.14M | 2.22M | 2.09M | 2.44M | 2.38M |
| Depreciation & Amortization | 6.80K | 6.80K | 6.80K | 6.80K | 6.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.08M | 4.45M | 6.66M | 5.58M | 3.99M |
| Operating Income | -4.08M | -4.45M | -3.24M | -5.46M | 2.01M |
| Income Before Tax | -3.64M | -4.02M | -2.89M | -5.05M | 1.99M |
| Income Tax Expenses | -720.30K | -- | -- | -- | 723.90K |
| Earnings from Continuing Operations | -2.92M | -4.02M | -2.89M | -5.05M | 1.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.92M | -4.02M | -2.89M | -5.05M | 1.27M |
| EBIT | -4.08M | -4.45M | -3.24M | -5.46M | 2.01M |
| EBITDA | -4.07M | -4.44M | -3.23M | -5.45M | 2.02M |
| EPS Basic | -0.18 | -0.26 | -0.19 | -0.35 | 0.11 |
| Normalized Basic EPS | -0.14 | -0.17 | -0.12 | -0.22 | 0.12 |
| EPS Diluted | -0.18 | -0.26 | -0.19 | -0.35 | 0.11 |
| Normalized Diluted EPS | -0.14 | -0.17 | -0.12 | -0.22 | 0.12 |
| Average Basic Shares Outstanding | 16.36M | 15.22M | 14.92M | 14.46M | 11.04M |
| Average Diluted Shares Outstanding | 16.36M | 15.22M | 14.92M | 14.46M | 11.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
